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pen access Abstract Four sensitive and selective stability-indicating methods for the determination of bupro-
pion hydrochloride in the presence of its alkaline degradates, related impurity, 3-chlorobenzoic
acid, and in its pharmaceutical formulation were developed. Method A is an isocratic reversed
phase HPLC, good separation between bupropion hydrochloride, its alkaline degradates and
related impurity was achieved using a mobile phase of 1.2% w/v ammonium dihydrogen phosphate
pH 4.5 and acetonitrile (80:20, v/v) and detection at 210 nm. Method B is based on the ﬁrst deriv-
ative (D1) measurement of the drug at 259 nm, zero contribution point of its alkaline degradates
and related impurity. Method C is based on the resolution of the drug, its alkaline degradates
and related impurity by ﬁrst derivative ratio spectra (DD1). Method D is based on the determina-
tion of bupropion hydrochloride and its impurity by the Q value method at 248 nm, 227 nm and at
isoabsorptive point 237 nm. These methods are successfully applied for the determination of bupro-
pion hydrochloride in bulk powder, pharmaceutical formulation and in the presence of its alkaline
degradates and related impurity. The results obtained are statistically analyzed and there are no05855446.
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Bupropion hydrochloride (Bup-HCl) is described chemically as
shown in Fig. 1 as (±)-2-(tert-butyl amino)-1-(3-chlorophenyl)
propan-1-one.1 The drug is an antidepressant that acts as nor-
epinephrine, dopamine reuptake inhibitor and nicotine antag-
onist. Bupropion hydrochloride is used also for depression,
smoking cessation, obesity and attention deﬁcit hyperactivity
disorder.2 Various methods were reported for the determina-
tion of Bup-HCl including spectrophotometry,3–5 potentiome-
try,3 conductometry,3 titrimetry,5 and polarography.6 HPLC
methods were used for the determination of Bup-HCl.7–9
HPLC tandem mass spectrometry also was used for the iden-
tiﬁcation and determination of the drug in human plasma,
whole blood and urinary metabolites.10–18 Electro kinetic chro-
matography was used for separation of bupropion enantio-
mers19 and their enantiomeric determination in human
plasma using coupled achiral-chiral liquid chromatography.20
A validated thin-layer and gas chromatography were used
for the determination of Bup-HCl in its pharmaceutical
formulation.21,22
A literature survey reveals that there is no stability indicat-
ing HPLC or spectrophotometric methods were published for
the drug. The novelty of this work is to establish stability indi-
cating HPLC and spectrophotometric methods for the deter-
mination of Bup-HCl in the presence of both its alkaline
degradates and its related impurity, 3-chlorobenzoic acid with
identiﬁcation of the degradates.
3-Chlorobenzoic acid is one of the Bup-HCl metabolites
and is physiologically inactive23,24 and is stated ofﬁcially as re-
lated impurity in the raw material and pharmaceutical formu-
lation.25 The proposed methods are simple, rapid, accurate,
reproducible and economical besides the HPLC method is less
time consuming than the ofﬁcial USP one.25
2. Experimental
2.1. Instrumentation
1. HPLC Agilent 1200 series was equipped with a model series
ED62962752 LC quaternary pump, Rheodyne injector Lot
ID 7725 with a 20 lL loop and UV detector DE71360313.
Separation and quantitation were made on column eclipse
XDB-C18, 4.6 · 150 mm, 5 lm particle size serial number:
USK H036684. The detector was set at k= 210 nm
(Germany).
2. A double beam UV–visible spectrophotometer (Shimadzu,
Japan) model UV-1601 PC with quartz cell of 1 cm path
length, was connected to IBM compatible computer and
a HP 600 inject printer was used. The spectral band width
was 2 nm and the wavelength scanning speed was
2800 nm min1. The absorbance spectra of the test and
reference solution were recorded over the range of 200–320 nm. The ﬁrst derivative and derivative ratio were
obtained using the accompanying software with Dk= 4
and scaling factor = 10.
3. Mass spectrometer GCMS-QP 1000 EX working by elec-
tronic ionization mode. Shimadzu (Japan).
4. PH meter HANAA 8417 (Portugal).
5. Photodegradator UV light source LPS-220 PTI model
A1010 (Italy).
6. TLC plates pre-coated with silica Gel GF, 0.25 mm thick-
ness, ﬂuorescent at 254 nm (E. Merck, Darmstadt,
Germany).
7. Sonicator, Bandelin-Sonorex TK (Germany).
8. Centrifuge Hettich (Germany).
2.2. Materials
2.2.1. Working standard
Bupropion hydrochloride was kindly supplied by Glaxo Smith
Kline (GSK), Cairo Egypt; its purity was 99.90% ±0.59
according to the ofﬁcial HPLC method.25
2.2.2. Pharmaceutical formulation
Wellbutrin SR tablets are labeled to contain 150 mg of
bupropion hydrochloride per tablet and manufactured by
Glaxo Smith Kline, Cairo, Egypt. Batch No. 090665A.
2.2.3. Degraded sample
2.2.3.1. Preparation of alkaline degradates. An accurately
weighed 100 mg of Bup-HCl was dissolved in 10 ml methanol
and transferred into 250 mL stopper conical ﬂask, 100 mL 5 M
aqueous sodium hydroxide solution was added and reﬂuxed
for 12 h. The solution was cooled at room temperature then
neutralized with 5 M hydrochloric acid, ﬁltered and evapo-
rated to residue, weighed and diluted to 50 mL with methanol
and ﬁltered if necessary. The solution was tested for complete
degradation by TLC using isopropanol–toluene–dichloro-
methane–acetic acid (5:5:5:0.5, by volume) as a developing sys-
tem, no spot was observed at Rf 0.25 corresponding for intact
Bup-HCl. Only 2 spots were observed, one at Rf 0.85 corre-
sponding to 3-chlorobenzoic acid and the other remain at
the starting line. The stock solution of the degradates was pre-
pared in methanol 1 mg mL1. The structure of the degradates
was elucidated using mass spectroscopy.
2.2.3.2. Preparation of acid degradates. Acid degradates were
prepared as mentioned above using 5 M hydrochloric acid
and neutralized with 5 M sodium hydroxide. The material
was tested for complete degradation as mentioned above.
2.2.3.3. Preparation of oxidative degradates. Using 10 mg Bup-
HCl and 1 mL hydrogen peroxide 30%, the solution was di-
luted with 25 mL water and reﬂuxed for 1 h. The material
was tested for complete degradation as above and conﬁrmed
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method.
2.2.3.4. Preparation of photodegradates. An amount of 100 mg
of Bup-HCl was dissolved in 100 mL methanol and subjected
to UV light source for 6 h.
The proposed alkaline, acidic, oxidative and photolytic
degradates were tested for complete degradation using HPLC
method.
2.2.4. Chemicals and reagents
All reagents and chemicals used were of analytical grade, and
the solvents were of HPLC and spectroscopic grade.
1. 3-Chlorobenzoic acid 99% Aldrich, related impurity of
Bup-HCl in USP.25
2. Acetonitrile and methanol of HPLC grade (SDFCL).
3. Dichloromethane, isopropanol (Fisher Scientiﬁc), hydro-
gen peroxide 30% (Merck), orthophosphoric acid, toluene,
glacial acetic acid, sodium hydroxide, ammonium acetate
(Adwic), hydrochloric acid (Riedel–de Ha¨en) and ammo-
nium dihydrogen phosphate (WINLAB).
4. The water for HPLC was prepared by double glass distilla-
tion and ﬁltration through a 0.45 lm membrane ﬁlter.
2.3. Chromatographic conditions
Analysis was carried out on Agilent 1200 series instrument.
However, for convenience, the elution was monitored at
210 nm. Separation was achieved by using ODS column
(Eclipse XDB 150 mm · 4.6 mm, 5 lm) with mobile phase of
(80:20, v/v) mixture of 1.2% w/v ammonium dihydrogen phos-
phate pH 4.5 adjusted with orthophosphoric acid if necessary
and acetonitrile. The mobile phase was ﬁltered using 0.45 lmFigure 1 The alkaline degradates of bupropion hydrochloride (a) sho
methyl-2-(3-chlorophenyl) acetic acid (c) and 3-chlorobenzoic acid (d)disposable ﬁlter (Millipore, Milford, MA) and degassed by
ultrasonic vibrations prior to use. The ﬂow rate of the mobile
phase was 1.5 mL min1. Twenty microliters of sample solu-
tion is injected each time.
2.4. Standard solutions
 Stock standard solutions of Bup-HCl, its alkaline degradates
and related impurity, 3-chlorobenzoic acid, 1 mg mL1
prepared in methanol (for HPLC, D1, DD1 and Q value).
 Working standard solutions of Bup-HCl, its alkaline
degradates and related impurity 200 lg mL1 prepared in
methanol (for HPLC) and 50 lg mL1 in methanol (for
D1, DD1, and Q value).
2.5. Laboratory prepared mixtures
Aliquots of Bup-HCl were accurately transferred into a series
of 10-mL volumetric ﬂasks, to these ﬂasks separate volumes of
the solution of alkaline degradates or related impurity are
added to prepare different mixtures containing 10–90% of
the alkaline degradates and related impurity and the volume
of each ﬂask was completed with the same solvent used in
the proposed methods.
3. Procedure
3.1. Construction of calibration curve
3.1.1. HPLC method
Aliquots of Bup-HCl working standard solution (200 lg mL1
in methanol) equivalent to 100–1000 lg were accurately trans-
ferred into a series of 10-mL volumetric ﬂasks, the volume waswing 1-(3-chlorophenyl)-1-hydroxy-2-propanone (b), 2-hydroxy-2-
.
Figure 2 (a) Chromatogram of mixture of bupropion hydrochloride 90 lg mL1 and its alkaline degradates 90 lg mL1. Showing: A –
bupropion hydrochloride; B – 1-(3-chlorophenyl)-1-hydroxy-2-propanone; C – 2-hydroxy-2-methyl-2-(3-chlorophenyl) acetic acid;
D – 3-chlorobenzoic acid. (b) Chromatogram of alkaline degradates 90 lg mL1 showing complete degradation. (c) Chromatogram of
acid degradates 90 lg mL1 showing incomplete degradation. (d) Chromatogram of oxidative degradates 90 lg mL1 showing incomplete
degradation.
52 S.S. Abbas et al.completed to the mark with methanol. Triplicate 20 lL injec-
tions were made for each concentration and chromatographed
under the condition described above. The calibration curve
was constructed and the regression equation was computed.
3.1.2. D1 method
Aliquots of Bup-HCl working standard solution (50 lg mL1
in methanol) equivalent to 20–250 lg were accurately trans-
ferred into a series of 10-mL volumetric ﬂasks, the volume
was completed to the mark with methanol. The values of D1amplitude using methanol as a blank were measured at
259 nm. The calibration curve was constructed and the regres-
sion equation was computed.
3.1.3. DD1 method
Aliquots of Bup-HCl working standard solution (50 lg mL1
in methanol) equivalent to 20–250 lg were accurately trans-
ferred into a series of 10-mL volumetric ﬂasks, the volume
was completed to the mark with methanol. Spectrum of work-
ing standard solution of Bup-HCl was divided by either the
Figure 3 Mass spectra of Bup-HCl (a) and its alkaline degradates (b–d).
Stability indicating HPLC and spectrophotometric 53spectrum of 10 lg mL1 alkaline degradates or 5 lg mL1 in
methanol related impurity. The DD1 values were calculated
for the obtained spectra with Dk= 4 and a scaling fac-
tor = 10. The amplitudes at 240 and 244.8 nm were measured
for the drug in the presence of alkaline degradates and related
impurity, respectively. The calibration curve was constructed
and the regression equation was computed.3.1.4. Q value method
Aliquots of Bup-HCl and 3-chlorobenzoic acid working stan-
dard solutions (50 lg mL1 in methanol) equivalent to 40–
160 lg were accurately transferred into a series of 10-mL
volumetric ﬂasks, the volume was completed to the mark with
methanol. This method is based on measuring the absorbance
at 237 nm of isoabsorptive point, at 248 and 227 nm
Table 1 System suitability parameters of the proposed HPLC method.
Product Symmetry Resolution Theoretical plates Retention time (min)
Bupropion hydrochloride 0.48 5714 6.9 ± 0.1
3.35
3-Chlorobenzoic acid 0.83 8207 5.8 ± 0.05
2.25
2-Hydroxy-2-methyl-2-(3-chlorophenyl) acetic acid 0.86 7380 5.3 ± 0.02
12.44
1-(3-Chlorophenyl)-1-hydroxy-2-propanone 0.91 6581 2.9 ± 0.07
Table 2 Characteristic parameters of bupropion hydrochloride by the proposed methods.
Parameters HPLC Derivative
spectrophotometry
Ratio derivative
in presence of
total degradates
Ratio derivative
in presence
of impurity
Q value for
the drug
Q value for
related
impurity
Range (lg mL1) 10–100 2–25 2–25 2–25 4–16 4–16
Linearity
Slope 66.271 0.0309 2.6934 2.1243 1.2981 1.9173
Intercept 29.935 0.0167 0.6116 0.579 0.255 0.4003
Correlation coeﬃcient (r) 0.9999 0.9999 0.9998 0.9998 0.998 0.997
RSD% of slope 0.23 0.19 0.04 0.16 1.59 1.92
RSD% of intercept 8.77 1.35 0.59 1.49 3.08 3.66
Mean ± RSD% (accuracy) 100.63 ± 1.12 99.97 ± 1.23 99.78 ± 0.91 99.35 ± 1.22 99.65 ± 1.38 100.40 ± 1.20
Precision RSD%
Repeatabilitya 1.22 1.35 1.59 1.57 0.84 1.08
Intermediate precisionb 1.84 1.72 1.92 1.86 1.98 1.53
Limit of detection (lg mL1) 0.49 0.49 0.34 0.43 0.58 0.39
Limit of quantitation (lg mL1) 1.65 1.62 1.15 1.42 1.93 1.30
a The intraday (n= 3), average of three different concentrations repeated three times within day.
b The interday (n= 3), average of three different concentrations repeated three times in three successive days.
54 S.S. Abbas et al.corresponding to the maxima for Bup-HCl and its related
impurity. Their absorptivity values at the selected wavelengths
were calculated.
3.2. Pharmaceutical formulation analysis
Ten tablets of Wellbutrin SR tablets were accurately weighed
and ﬁnely powdered. A portion of the powder equivalent to
100 mg of Bup-HCl was accurately weighed, dissolved in
70 mL of methanol with the aid of ultrasound for 30 min. A
sufﬁcient quantity of methanol was added to produce
100 mL. The solution was centrifuged for 1 h at 3500 rpm
and then ﬁltered; the ﬁnal concentration was 1 mg mL1. Fur-
ther dilutions of the sample solution were carried out with
methanol to prepare the working standard solution. The gen-
eral procedures for HPLC, D1, DD1 and Q value methods de-
scribed under construction calibration were followed and the
concentration of Bup-HCl was calculated.
4. Results and discussion
The International Conference of Harmonization (ICH) guide-
line entitled ‘‘stability testing of new drugs substances and
products’’ requires the stress testing to be carried out to eluci-
date the inherent stability characteristics of the active sub-
stance.26 An ideal stability indicating method is one that
quantiﬁes the standard drug alone and also resolves its degra-
dation products and related impurity.Bupropion hydrochloride was subjected to alkali, acid
hydrolysis, oxidation and UV light. Reﬂuxing Bup-HCl with
5 M sodium hydroxide, complete degradation results in
formation of 3 degradates conﬁrmed and separated by HPLC
at retention time 2.9, 5.3 and 5.8 min. for 1-(3-chlorophenyl)-1-
hydroxy-2-propanone, 1-(3-chlorophenyl)-1,2-propanedione
which undergoes benzil-benzilic acid rearrangement in alkaline
medium to form 2-hydroxy-2-methyl-2-(3-chlorophenyl) acetic
acid and the third one was 3-chlorobenzoic acid, respectively,
while no peak at retention time 6.9 min was observed corre-
sponding of Bup-HCl (Figs. 1 and 2).
Upon reﬂuxing Bup-HCl with 5 M HCl for 24 h,
incomplete degradation results, and formation of 1-(3-chloro-
phenyl)-1-hydroxy-2-propanone and 3-chlorobenzoic acid.
Reﬂux with hydrogen peroxide for 1 hour, incomplete
degradation of Bup-HCl and formation of 3-chlorobenzoic
acid. Exposure of the methanolic solution of Bup-HCl to
photo degradation UV lamp for 6 hours, the drug remains
stable.
This was conﬁrmed by mass spectrometry (Fig. 3) showing
mass ion peak m/z at 184, 199 and 156 for the degradates:
1-(3-chlorophenyl)-1-hydroxy-2-propanone, 2-hydroxy-2-
methyl-2-(3-chlorophenyl) acetic acid and 3-chlorobenzoic
acid. The latter is stated ofﬁcially as related impurity was also
found as one of the degradation products.
(a) HPLC method
Several trials were carried out to obtain a good resolution
between the drug and its alkaline degradates or impurity.
Figure 4 Zero order absorption spectra of bupropion hydrochloride 10 lg mL1 in methanol (____), its alkaline degradates 10 lg mL1
in methanol (____) and 3-chlorobenzoic acid 10 lg mL1 in methanol (...........).
Figure 5 First derivative absorbance of bupropion hydrochloride 10 lg mL1 in methanol showing the selected wavelength at 259 nm
(____), its alkaline degradates 10 lg mL1 in methanol (____) and 3-chlorobenzoic acid 10 lg mL1 in methanol (..........).
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different ratios, different pH and ﬂow rates.
The best resolution with sharp and symmetric peaks were
obtained upon using 1.2% ammonium dihydrogen phosphate
pH 4.5 and acetonitrile (80:20, v/v), and a ﬂow rate of
1.5 mL min1. The retention time for Bup-HCl was found to
be 6.9 ± 0.2 min. The same mobile phase with pH 6 delayed
the retention time of the drug to 14 min.
System suitability of the procedure is shown in Table 1.
Characteristic parameters for regression equation of HPLC
method and correlation coefﬁcient obtained by least squares
treatment of the results were given in Table 2. The regression
equation was computed and found to be:
Y ¼ 66:271C 29:935 r ¼ 0:9999
where Y is the peak area, C is the concentration of Bup-HCl in
lg mL1 and r is the correlation coefﬁcient.(b) Spectrophotometric methods
(1) D1 method
The zero-order absorption spectra of Bup-HCl, alkaline
degradates and 3-chlorobenzoic acid showed severe overlap-
ping which interfere with the direct determination of Bup-
HCl (Fig. 4). Derivative spectrophotometry is an analytical
technique of great utility for extracting both qualitative and
quantitative information from spectra composed of unresolved
bands, and for eliminating the effect of baseline shift.27 A ra-
pid, simple, and low cost spectrophotometric method based
on measuring the peak amplitude of D1 spectrum of Bup-
HCl at 259 nm (corresponding to zero-contribution of the
degradates and related impurity) was developed with good
selectivity without interference of alkaline degradates and re-
lated impurity. In order to optimize D1 method, different sol-
vents, smoothing and scaling factors were tested, methanol is
the best solvent, a smoothing factor Dk= 4 and a scaling
Figure 6 First derivative of ratio spectra of bupropion hydrochloride 2–25 lg mL1 with the divisor of alkaline degradates 10 lg mL1
in methanol showing the selected wavelength at 240 nm.
Figure 7 First derivative of ratio spectra of bupropion hydrochloride 2–25 lg mL1 with the divisor of impurity 5 lg mL1 in methanol
showing the selected wavelength at 244.8 nm.
56 S.S. Abbas et al.factor = 10. Fig. 5 shows a suitable signal to noise ratio and
the spectra show good resolution. A linear correlation was
obtained between peak amplitude at 259 nm and the corre-
sponding concentration in the range of 2–25 lg mL1, from
which the linear regression equation was computed and found
to be:
Y ¼ 0:0309C 0:0167 r ¼ 0:9999
where Y is the peak amplitude at 259 nm, C is the concentra-
tion of Bup-HCl in lg mL1 and r is the correlation
coefﬁcient.
(2) DD1 method
In order to improve the selectivity of the analysis of
Bup-HCL in the presence of its alkaline degradates or related
impurity, DD1 spectrophotometric method was established.
The main advantage of the method is that the whole spectrum
of interfering substance is canceled. Accordingly, the choice ofthe wavelength selected for calibration is not critical as in ﬁrst
derivativeD1method. In order to optimizeDD1method, several
divisor concentrations of the alkaline degradates and related
impurity were used and different smoothing and scaling factors
were tested. The best result was obtained when using 10 and
5 lg mL1 as a divisor for alkaline degradates and related impu-
rity at 240 and 244.8 nm, respectively, using Dk= 4 and scaling
factor = 10 as shown in Figs. 6 and 7. Beer’s law was obeyed in
concentration range 2–25 lg mL1, from which the linear
regression equation was computed as shown in Table2.
Y1 ¼ 2:6934Cþ 0:6116 r¼ 0:9998 in the presence of degradates
Y2 ¼ 2:1243Cþ 0:5790 r¼ 0:9998 in the presence of impurity
where Y1 and Y2 are the peak amplitudes at 240 and 244.8 nm,
C is the concentration of Bup-HCl in lg mL1 and r is the
correlation coefﬁcient.
Table 3 Evaluation of the selectivity of the proposed methods for the determination of bupropion hydrochloride in the presence of its
alkaline degradates and its related impurity.
Sample
number
% Added
of alkaline
degradates
or impurity
Methods
HPLC D1 DD1 Q value
In presence of
alkaline
degradates
In presence of
impurity
In presence of
alkaline
degradates
In presence
of impurity
In presence
of alkaline
degradates
In presence
of impurity
1 10 99.98 98.85 98.12 101.59 98.69 100.31
2 20 99.00 99.50 101.60 101.60 98.36 98.36 101.72
3 50 101.35 101.53 98.98 100.77 101.9 100.85 101.84
4 70 101.85 101.96 102.62 102.62 98.53 98.53 98.12
5 80 100.99 98.65 102.05 102.05 98.25 98.25 99.58
6 90 98.35 99.56 101.69 98.14 98.25 98.88
Mean ± RSD% 100.25 ± 1.38 100.01 ± 1.40 100.84 ± 1.82 101.13 ± 1.57 99.00 ± 1.45 99.20 ± 1.12 100.32 ± 1.79
Table 4 Determination of bupropion hydrochloride in pharmaceutical formulation by the proposed methods and application of
standard addition technique.
Parameter HPLC Derivative
spectrophotometry
Derivative ratio
in presence of
total degradates
Derivative ratio
in presence
of impurity
Q value USP25,c
Mean ± RSD% 99.82 ± 0.86 99.42 ± 1.61 98.88 ± 0.85 99.12 ± 1.02 99.02 ± 1.29 99.96 ± 1.18
Variance 0.73 2.56 0.70 1.03 1.62 1.38
n 5 5 5 5 5 5
t-Test (2.306)a 0.84 0.56 0.14 0.27 0.26
F-ratio (6.39)a 1.89 1.85 1.97 1.35 1.17
Recoveryb 100.07 ± 1.83 99.59 ± 1.25 98.77 ± 1.60 98.86 ± 1.39 99.97 ± 1.76
a Theoretical value for t and F for P= 0.05.
b For standard addition of different concentrations of bupropion hydrochloride.
c Ofﬁcial HPLC method using C18 (4.6 mm · 15 cm, 5 lm) column, mobile phase methanol and pH 7 phosphate buffer (65:35), ﬂow rate
1.2 mL min1 and detection at 224 nm. The retention time of bupropion hydrochloride was at 12.5 min.
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The absorbance ratio method is a modiﬁcation of the simul-
taneous equations. Q analysis is based on the relationship be-
tween absorbance ratio value of binary mixture and relative
concentrations of such a mixture.28 This method was used
for the determination of Bup-HCl and its related impurity in
the presence of each other. From the overlain spectrum of
Bup-HCl and its impurity, three wavelengths were selected,
248 nm, the maximum of the drug, 237 nm, the isoabsorptive
point for both Bup-HCl and its impurity, and 227 nm corre-
sponding to related impurity 3-chlorobenzoic acid (Fig. 4).
The method employs Q values and the concentration of Bup-
HCl was determined by using the following formula:
C1 ¼ Q0 Q2
Q1 Q2
 A
a1
Q0 ¼
Absorbance of sample at 248 nm
Absorbance of sample at 237 nm
Q1 ¼
Absorptivity of drug at its maximum 248 nm
Absorptivity of drug at isoabsorptive point 237 nm
Q2 ¼
Absorptivity of impurity at its maximum 248 nm
Absorptivity of impurity at isoabsorptive point 237 nm
A ¼ Absorbance of mixture at isoabsorptive point
a1 ¼ Absorptivity of cited drug at isoabsorptive pointAnd the concentration of related impurity was determined by
using the following formula:
C2 ¼ Q
0
0 Q4
Q3 Q4
 B
b1
Q00 ¼
Absorbance of sample at 227 nm
Absorbance of sample at 237 nm
Q3 ¼
Absorptivity of impurity at its maximum 227 nm
Absorptivity of impurity at isoabsorptive point 237 nm
Q4 ¼
Absorptivity of drug at its maximum of impurity 227 nm
Absorptivity of drug at isoabsorptive point 237 nm
B ¼ Absorbance of mixture at isoabsorptive point
b1 ¼ Absorptivity of impurity at isoabsorptive point
Linearity was obeyed in concentration range 4–16 lg mL1,
from which the linear regression equation was computed as
shown in Table 2.
Y1 ¼ 1:2981C1 þ 0:2255 r ¼ 0:9975
Y2 ¼ 1:9173C2 þ 0:4003 r ¼ 0:9970
where Y1 and Y2 are the Q0 and Q
0
0 values of Bup-HCl and its
related impurity, respectively, C1 and C2 are the concentra-
tions of Bup-HCl and its related impurity in lg mL1 and r
is the correlation coefﬁcient.
Table 5 Statistical comparison between the proposed methods and ofﬁcial USP method in bulk powder.
Parameter HPLC Derivative
spectrophotometry
Ratio derivative
in presence of
total degradates
Ratio derivative
in presence
of impurity
Q value USP25,c
Meana ± RSD% 100.63 ± 1.12 99.97 ± 1.23 99.78 ± 0.91 99.35 ± 1.22 99.65 ± 1.38 99.90 ± 0.59
Variance 1.27 1.52 0.82 1.46 1.89 0.35
n 5 5 5 5 5 5
t-Test (2.306)b 0.25 0.91 0.81 0.39 0.72
F-ratio (6.39)b 3.68 4.39 2.39 4.23 5.48
a Average of ﬁve determinations.
b Values of theoretical t and F values at P= 0.05.
c Ofﬁcial HPLC method using C 8 (3.9 mm · 15 cm, 5 lm) column, mobile phase 0.025 M phosphate buffer, methanol, tetrahydrofuran
(51:39:11 v/v), ﬂow rate 1.1 mL min1 and detection at 250 nm. The retention time of bupropion hydrochloride was at 27.4 min.
58 S.S. Abbas et al.The Q method was highly selective towards the cited drug
and its impurity and determines the cited drug in the presence
of 20–80% of its impurity and vice versa.
The proposed HPLC, D1 and DD1 methods were checked
by the analysis of laboratory prepared mixtures of Bup-HCl
and its alkaline degradates or related impurity in different ra-
tios as presented in Table 3. Bupropion hydrochloride could be
determined in the presence of up to 90% of alkaline degradates
or related impurity.
Method validation was performed according to ICH guide-
lines26 for all the proposed methods. Table 2 shows results of
accuracy, repeatability and intermediate precision of the
methods.
The proposed methods were applied to the determination of
Bup-HCl in commercial tablets. Five replicate determinations
were made and satisfactory results were obtained in good
agreement with the labeled claims (Table 4). Statistical com-
parison of the results was performed with regard to accuracy
and precision using student’s t-test and the F-ratio at 95% con-
ﬁdence level (Table 4). There is no signiﬁcant difference be-
tween the proposed methods and the ofﬁcial one with regard
to accuracy and precision.
The validity of the proposed methods was assessed by
applying the standard addition technique, which showed accu-
rate results and there is no interference from excipients as
shown in Table 4.
Statistical comparison of the results of analysis of bulk
powder obtained by the proposed methods and the ofﬁcial
HPLC method25 was also done using student’s t-test and the
F-ratio at 95% conﬁdence level (Table 5), it is clear that there
is no signiﬁcant difference between the proposed methods with
regard to accuracy and precision.
5. Conclusion
The proposed HPLC and spectrophotometric methods provide
simple, accurate and reproducible procedure for the determi-
nation of Bup-HCl in pharmaceutical formulations, without
any interference from the excipients and in the presence of
its alkaline degradates and related impurity. The chromato-
graphic method was found to be more speciﬁc and selective
than the spectrophotometric methods, while the spectrophoto-
metric methods had the advantage of low cost, rapid and envi-
ronmental protecting. The proposed methods were completely
validated and can be used for the routine analysis of Bup-HClin quality control laboratories, where economy and time are
essential.
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